Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Non-Current Deffered Revenue: 2020-2022

Historic Non-Current Deffered Revenue for Therapeutics (RAPT) over the last 2 years, with Mar 2022 value amounting to $241,000.

  • Therapeutics' Non-Current Deffered Revenue fell 88.83% to $241,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $241,000, marking a year-over-year decrease of 88.83%. This contributed to the annual value of $2.1 million for FY2021, which is 1.60% down from last year.
  • Latest data reveals that Therapeutics reported Non-Current Deffered Revenue of $241,000 as of Q1 2022, which was down 88.79% from $2.1 million recorded in Q4 2021.
  • Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $3.3 million during Q1 2020, with a 5-year trough of $241,000 in Q1 2022.
  • Its 3-year average for Non-Current Deffered Revenue is $2.1 million, with a median of $2.2 million in 2021.
  • Data for Therapeutics' Non-Current Deffered Revenue shows a maximum YoY crashed of 88.83% (in 2022) over the last 5 years.
  • Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $2.2 million in 2020, then fell by 1.60% to $2.1 million in 2021, then slumped by 88.83% to $241,000 in 2022.
  • Its last three reported values are $241,000 in Q1 2022, $2.1 million for Q4 2021, and $2.1 million during Q3 2021.